PRQR – proqr therapeutics n.v. - ordinary shares (US:NASDAQ)

News

ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board [Yahoo! Finance]
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com